Carolyn Bertozzi is
a leading expert on bioorthogonal chemistry.
In fact, she is credited with developing the field. She’ll be keynoting on Bioorthogonal
Chemistries for Biomolecular Engineering at this year’s Bioconjugates: From Targets to
Therapeutics conference. We were
able to pick Carolyn’s brain about some of the issues in the field today. One of our questions to her:
How exactly are researchers using these
bioorthogonal reactions as experimental tools?
Well, it has
turned out to be a pretty general platform for use in bioconjugation in many
different kinds of settings. For example, from the perspective of making
chemically modified protein drugs, which is a major component of biopharma
efforts, bioorthogonal chemistry is really useful.
So, people have
used it to attach bio-ethylene glycol change to proteins. So, it’s a PEGylate
protein. In many ways, using bioorthogonal chemistry to generate such
chemically modified proteins is much cleaner and easier to control than more
conventional chemistries of bioconjugation, like the kinds of chemistries that
involve the side chains of glycines and cysteines; these are much harder to
control. Just to modify a protein with a cargo molecule, whether it’s for a
therapeutic purpose like an antibody drug conjugate, which is going to be the
subject of my presentation, or for PEGylation or even just to attach
biophysical probes to proteins, like a fluorescent die for imaging purposes or
cystoscopy purposes. These are all areas in which bioorthogonal chemistries
turned out to be quite useful.
Beyond that, it’s
turned out to be a really nice experimental platform for in vivo imaging in
live cells and also live organisms. There has been a lot of activity in
basically delivering a bioorthogonal functional group to a protein or a nucleic
acid or a polysaccharide in the context of live cells or model organisms and
then using the bioorthogonal chemistry to conjugate that functional group with
a probe molecule in the living system. Because the chemistry is orthogonal to
the biology, you can actually do these reactions in organisms without any
unwanted side effects or off-target reactivity. So, in my lab we use
bioorthogonal chemistry to image self-surface sugar molecules. That’s an interest of ours.
We, in other labs,
have used bioorthogonal chemistry to image bacterial pethano glycan and to look
at the dynamic nature of that structure in the context of pathogenesis. People
have used bioorthogonal chemistry to image proteins that had been recently
biosynthesized to understand how protein biosynthesis changes as a function of
time during physiological process or as a function of space across different
components of the cell.
So, I think
imaging and bioconjugation or making chemically modified protein drugs, these
are the big applications that I’ve been reading about in recent years.
Click here to download the entire podcast and
hear more from Carolyn.
You can hear more
from Carolyn at this year’s Bioconjugates: From Targets to Therapeutics
conference, June 4-6th, San Francisco, CA. SAVE 20%
on the standard rate. Use discount code D14199BLOG.
Register here.
Follow us on Twitter
Like us on Facebook
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment